Long-term follow-up results of Chronic myeloid leukemia by RQ-PCR monitoring of BCR-ABL transcripts in imatinib era -a single institutional experience

Tzu Chuan Huang, Hsiu Man Hung, Ping Ying Chang, Ming Shen Dai, Ching Liang Ho, Yeu Chin Chen, Tsu Yi Chao, Woei Yau Kao

研究成果: 雜誌貢獻文章

摘要

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome and peripheral leukocytosis which prior to the imatinib era, eventually led to acute leukemia within 3-5 years. According to current treatment guidelines, the monitoring of molecular response by RQ-PCR has been considered an important part of management of patients on tyrosine kinase inhibitor (TKI) therapy. Patients and Methods: This retrospective study aimed to evaluate the characteristics and treatment outcomes of CML patients treated at our institution from July 2004 until February 2012. The molecular response was monitored by RQ-PCR, and the impact of early molecular response on overall survival (OS) and event free survival (EFS) was also analyzed. Results: A total of 50 patient records were reviewed. The mean age was 43.5 years. Forty patients (80%) were diagnosed as CML in CP, while 4 (8%) were in AP and 6 (12 %) in BC. Patients with CML in CP had significantly longer mean survival of 109.4 months, compared with 58.5 months in AP and 48.9 months in BC groups (p=0.001). There was no significant OS benefit associated with MMR at 12 months (p=0.86) and 18 months (p=0.69). Early reduction of more than 10% of BCR-ABL transcripts at 3 months was related to high probability of achieving MMR at 12 and 18-month landmarks. In addition, MMR at 18 months and 10% or greater BCR-ABL reduction at 3 months were significantly associated with durable EFS (p=0.011 and p=0.015 respectively). Conclusions: The current analysis in our cohort of patients from Taiwan confirmed the efficacy and safety of imatinib therapy seen in larger randomized trials in CML patients. Early achievement of molecular response improved durable EFS, but not OS.
原文英語
頁(從 - 到)271-278
頁數8
期刊Journal of Medical Sciences (Taiwan)
32
發行號6
出版狀態已發佈 - 2012

指紋

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Polymerase Chain Reaction
Disease-Free Survival
Survival
Philadelphia Chromosome
Myeloproliferative Disorders
Imatinib Mesylate
Leukocytosis
Taiwan
Protein-Tyrosine Kinases
Leukemia
Therapeutics
Retrospective Studies
Guidelines
Safety

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Long-term follow-up results of Chronic myeloid leukemia by RQ-PCR monitoring of BCR-ABL transcripts in imatinib era -a single institutional experience. / Huang, Tzu Chuan; Hung, Hsiu Man; Chang, Ping Ying; Dai, Ming Shen; Ho, Ching Liang; Chen, Yeu Chin; Chao, Tsu Yi; Kao, Woei Yau.

於: Journal of Medical Sciences (Taiwan), 卷 32, 編號 6, 2012, p. 271-278.

研究成果: 雜誌貢獻文章

Huang, Tzu Chuan ; Hung, Hsiu Man ; Chang, Ping Ying ; Dai, Ming Shen ; Ho, Ching Liang ; Chen, Yeu Chin ; Chao, Tsu Yi ; Kao, Woei Yau. / Long-term follow-up results of Chronic myeloid leukemia by RQ-PCR monitoring of BCR-ABL transcripts in imatinib era -a single institutional experience. 於: Journal of Medical Sciences (Taiwan). 2012 ; 卷 32, 編號 6. 頁 271-278.
@article{c224f2b7efe04835a5c74f8eea026abf,
title = "Long-term follow-up results of Chronic myeloid leukemia by RQ-PCR monitoring of BCR-ABL transcripts in imatinib era -a single institutional experience",
abstract = "Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome and peripheral leukocytosis which prior to the imatinib era, eventually led to acute leukemia within 3-5 years. According to current treatment guidelines, the monitoring of molecular response by RQ-PCR has been considered an important part of management of patients on tyrosine kinase inhibitor (TKI) therapy. Patients and Methods: This retrospective study aimed to evaluate the characteristics and treatment outcomes of CML patients treated at our institution from July 2004 until February 2012. The molecular response was monitored by RQ-PCR, and the impact of early molecular response on overall survival (OS) and event free survival (EFS) was also analyzed. Results: A total of 50 patient records were reviewed. The mean age was 43.5 years. Forty patients (80{\%}) were diagnosed as CML in CP, while 4 (8{\%}) were in AP and 6 (12 {\%}) in BC. Patients with CML in CP had significantly longer mean survival of 109.4 months, compared with 58.5 months in AP and 48.9 months in BC groups (p=0.001). There was no significant OS benefit associated with MMR at 12 months (p=0.86) and 18 months (p=0.69). Early reduction of more than 10{\%} of BCR-ABL transcripts at 3 months was related to high probability of achieving MMR at 12 and 18-month landmarks. In addition, MMR at 18 months and 10{\%} or greater BCR-ABL reduction at 3 months were significantly associated with durable EFS (p=0.011 and p=0.015 respectively). Conclusions: The current analysis in our cohort of patients from Taiwan confirmed the efficacy and safety of imatinib therapy seen in larger randomized trials in CML patients. Early achievement of molecular response improved durable EFS, but not OS.",
keywords = "BCR-ABL transcript, Chronic myeloid leukemia, Imatinib, RQ-PCR",
author = "Huang, {Tzu Chuan} and Hung, {Hsiu Man} and Chang, {Ping Ying} and Dai, {Ming Shen} and Ho, {Ching Liang} and Chen, {Yeu Chin} and Chao, {Tsu Yi} and Kao, {Woei Yau}",
year = "2012",
language = "English",
volume = "32",
pages = "271--278",
journal = "Journal of Medical Sciences",
issn = "1011-4564",
publisher = "國防醫學院",
number = "6",

}

TY - JOUR

T1 - Long-term follow-up results of Chronic myeloid leukemia by RQ-PCR monitoring of BCR-ABL transcripts in imatinib era -a single institutional experience

AU - Huang, Tzu Chuan

AU - Hung, Hsiu Man

AU - Chang, Ping Ying

AU - Dai, Ming Shen

AU - Ho, Ching Liang

AU - Chen, Yeu Chin

AU - Chao, Tsu Yi

AU - Kao, Woei Yau

PY - 2012

Y1 - 2012

N2 - Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome and peripheral leukocytosis which prior to the imatinib era, eventually led to acute leukemia within 3-5 years. According to current treatment guidelines, the monitoring of molecular response by RQ-PCR has been considered an important part of management of patients on tyrosine kinase inhibitor (TKI) therapy. Patients and Methods: This retrospective study aimed to evaluate the characteristics and treatment outcomes of CML patients treated at our institution from July 2004 until February 2012. The molecular response was monitored by RQ-PCR, and the impact of early molecular response on overall survival (OS) and event free survival (EFS) was also analyzed. Results: A total of 50 patient records were reviewed. The mean age was 43.5 years. Forty patients (80%) were diagnosed as CML in CP, while 4 (8%) were in AP and 6 (12 %) in BC. Patients with CML in CP had significantly longer mean survival of 109.4 months, compared with 58.5 months in AP and 48.9 months in BC groups (p=0.001). There was no significant OS benefit associated with MMR at 12 months (p=0.86) and 18 months (p=0.69). Early reduction of more than 10% of BCR-ABL transcripts at 3 months was related to high probability of achieving MMR at 12 and 18-month landmarks. In addition, MMR at 18 months and 10% or greater BCR-ABL reduction at 3 months were significantly associated with durable EFS (p=0.011 and p=0.015 respectively). Conclusions: The current analysis in our cohort of patients from Taiwan confirmed the efficacy and safety of imatinib therapy seen in larger randomized trials in CML patients. Early achievement of molecular response improved durable EFS, but not OS.

AB - Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome and peripheral leukocytosis which prior to the imatinib era, eventually led to acute leukemia within 3-5 years. According to current treatment guidelines, the monitoring of molecular response by RQ-PCR has been considered an important part of management of patients on tyrosine kinase inhibitor (TKI) therapy. Patients and Methods: This retrospective study aimed to evaluate the characteristics and treatment outcomes of CML patients treated at our institution from July 2004 until February 2012. The molecular response was monitored by RQ-PCR, and the impact of early molecular response on overall survival (OS) and event free survival (EFS) was also analyzed. Results: A total of 50 patient records were reviewed. The mean age was 43.5 years. Forty patients (80%) were diagnosed as CML in CP, while 4 (8%) were in AP and 6 (12 %) in BC. Patients with CML in CP had significantly longer mean survival of 109.4 months, compared with 58.5 months in AP and 48.9 months in BC groups (p=0.001). There was no significant OS benefit associated with MMR at 12 months (p=0.86) and 18 months (p=0.69). Early reduction of more than 10% of BCR-ABL transcripts at 3 months was related to high probability of achieving MMR at 12 and 18-month landmarks. In addition, MMR at 18 months and 10% or greater BCR-ABL reduction at 3 months were significantly associated with durable EFS (p=0.011 and p=0.015 respectively). Conclusions: The current analysis in our cohort of patients from Taiwan confirmed the efficacy and safety of imatinib therapy seen in larger randomized trials in CML patients. Early achievement of molecular response improved durable EFS, but not OS.

KW - BCR-ABL transcript

KW - Chronic myeloid leukemia

KW - Imatinib

KW - RQ-PCR

UR - http://www.scopus.com/inward/record.url?scp=84872837052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872837052&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84872837052

VL - 32

SP - 271

EP - 278

JO - Journal of Medical Sciences

JF - Journal of Medical Sciences

SN - 1011-4564

IS - 6

ER -